Purpose: Amblyopic patients, or their parents, often want to know the potential for success before committing to treatment. Recent reports have indicated that the pattern visual evoked potential (pVEP) can be used as a predictor of the success of amblyopia therapy. Unfortunately, these studies did not determine if acuity estimates from pVEPs could accurately predict the acuity post-treatment. Furthermore, pVEPs are not always practical to obtain because of the time necessary to acquire the data. Sweep VEPs (sVEP) offer the advantage of rapidly estimating visual acuity in amblyopic patients. In this retrospective study, the relationship between sVEP acuities measured pre-amblyopic therapy and Snellen acuities measured post-amblyopic therapy was determined.
Methods: Seventeen patients with amblyopia were studied. Monocular sVEP and Snellen acuities were determined pre-amblyopic therapy and Snellen acuities were determined post-amblyopic therapy. An Enfant 4010 computer system was used to produce the stimuli, record the VEPs, and extrapolate the acuity. The stimuli were horizontally oriented, sine wave gratings (11 spatial frequencies from 2 to 24 cpd) with a contrast of 80%, counterphased at 7.5 Hz. Standard VEP recording techniques were employed. Therapy consisted of the full refractive correction and occlusion combined with active vision therapy.
Results: The patients demonstrated a significant improvement in pre- to post-amblyopic therapy Snellen acuities (P < 0.00001). The intraclass correlation coefficient (r (i)) between the pre-therapy sVEP acuities and the post-therapy Snellen acuities was 0.73. A paired t-test did not find a significant difference between the two sets of data (P = 0.94). For the amblyopes in this study, the average difference (+/-SD) in the sVEP acuity estimate and the final Snellen visual acuity was +0.002 +/- 0.123 logMAR acuity lines.
Conclusion: The results indicate that pre-amblyopic therapy sVEP acuity can be a good predictor of post-amblyopic therapy Snellen acuity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10633-007-9048-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
One-Year Outcomes in Subjects Developing Macular Neovascularization While Undergoing Avacincaptad Pegol Therapy for Geographic Atrophy.
Clin Ophthalmol
January 2025
Department of Ophthalmology, New Vision Eye Center, Vero Beach, FL, USA.
Purpose: To assess the 12-month outcomes in subjects developing macular neovascularization (MNV) during intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Methods: This research was conducted as a case-controlled, retrospective study of AMD subjects undergoing IVA treatment for GA from two private practice institutions. Subjects were divided into 1) a Study Group of patients who developed MNV and then underwent anti-vascular endothelial growth factor (VEGF) therapy during the study period, and 2) a Control Group of patients who were complication-free during the study period.
Efficacy of Split-Thickness Thin Amniotic Membrane Graft for Closure of Refractory or Large Macular Holes.
Retina
January 2025
Kresge Eye Institute/Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Purpose: To assess the effectiveness of split-thickness amniotic membrane (SAM) grafts in achieving closure of refractory or large macular holes (MH).
Methods: This retrospective study reviewed data from patients who underwent surgical repair of MHs using SAM grafts between January 2019 and December 2023. Key parameters, including best-corrected visual acuity (BCVA) and MH size, were evaluated both preoperatively and postoperatively.
Presumed Sympathetic Ophthalmia After Diode Laser Cyclophotocoagulation for Neovascular Glaucoma: A Case Series.
Ocul Immunol Inflamm
January 2025
Ophthalmology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Purpose: To describe a case series of presumed Sympathetic Ophthalmia (SO) triggered by diode laser cyclophotocoagulation (CPC) for the treatment of neovascular glaucoma.
Methods: Patients developing bilateral granulomatous uveitis after CPC between 2014 and 2024. Cases with prior ocular trauma or penetrating ocular surgery were excluded.
Severe Microbial Keratitis in Virgin and Transplanted Cornea-Probability of Visual Acuity Improvement.
J Clin Med
December 2024
Department of Ophthalmology, Medical University of Warsaw, Sierakowskiego 13, 01-756 Warsaw, Poland.
To evaluate visual acuity improvement and identify contributing factors in patients with severe keratitis affecting both virgin and transplanted corneas, treated at a hospital. A retrospective analysis was conducted on 497 patients with unilateral corneal ulcers treated at a tertiary referral center between 2008 and 2023. Data included distance (BCVA) and near best-corrected visual acuity at initial presentation and at discharge, treatments before hospital admission, demographic details, risk factors, clinical signs and symptoms, ancillary test results, and management strategies.
View Article and Find Full Text PDFSafety and Vision Outcomes Following Gene Therapy for Bietti Crystalline Dystrophy: A Nonrandomized Clinical Trial.
JAMA Ophthalmol
January 2025
Xiamen Eye Center of Xiamen University, Xiamen, Fujian, China.
Importance: Bietti crystalline dystrophy (BCD) is a severe genetic retinopathy caused by variants in the CYP4V2 gene. Currently, there is no approved treatment for BCD.
Objective: To evaluate safety and vision outcomes following gene therapy with adeno-associated virus (AAV) encoding CYP4V2 (rAAV-hCYP4V2, NGGT001 [Next Generation Gene Therapeutics]).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!